Reports Q4 revenue $2.4B, consensus $2.47B. President and CEO Christopher A. Viehbacher said: “2023 was a year of transformation for Biogen as we saw approval for four first-in-class medicines while we realigned our cost structure, remained prudent in allocating shareholder capital, and reprioritized our pipeline. We believe with these key elements in place we are now well positioned to return Biogen to sustainable growth. As we look to 2024, our focus is on operational execution, including building upon the progress of our recent new product launches. We believe this will allow us to continue to advance our goal of a new Biogen that creates enhanced value for patients and our shareholders.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BIIB:
- Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia
- Is BIIB a Buy, Before Earnings?
- Aptar Digital Health enters enterprise agreement with Biogen
- QQQ ETF Update, 2/1/2024
- William Blair biotech analyst to hold an analyst/industry conference call
